Chang-Zheng Du1, Yong-Chun Chen, Yong Cai, Wei-Cheng Xue, Jin Gu. 1. Department of Colorectal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Abstract
AIM: To evaluate the oncologic outcomes of primary and post-irradiated early stage rectal cancer and the effectiveness of adjuvant chemotherapy for rectal cancer patients. METHODS: Eighty-four patients with stage I rectal cancer after radical surgery were studied retrospectively and divided into ypstage I group (n = 45) and pstage I group (n = 39), according to their preoperative radiation, and compared by univariate and multivariate analysis. RESULTS: The median follow-up time of patients was 70 mo. No significant difference was observed in disease progression between the two groups. The 5-year disease-free survival rate was 84.4% and 92.3%, respectively (P = 0.327) and the 5-year overall survival rate was 88.9% and 92.3%, respectively, for the two groups (P = 0.692). The disease progression was not significantly associated with the pretreatment clinical stage in ypstage I group. The 5-year disease progression rate was 10.5% and 19.2%, respectively, for the patients who received adjuvant chemotherapy and for those who rejected chemotherapy in the ypstage I group (P = 0.681). CONCLUSION: The oncologic outcomes of primary and post-irradiated early stage rectal cancer are similar. Patients with ypstage I rectal cancer may slightly benefit from adjuvant chemotherapy.
AIM: To evaluate the oncologic outcomes of primary and post-irradiated early stage rectal cancer and the effectiveness of adjuvant chemotherapy for rectal cancerpatients. METHODS: Eighty-four patients with stage I rectal cancer after radical surgery were studied retrospectively and divided into ypstage I group (n = 45) and pstage I group (n = 39), according to their preoperative radiation, and compared by univariate and multivariate analysis. RESULTS: The median follow-up time of patients was 70 mo. No significant difference was observed in disease progression between the two groups. The 5-year disease-free survival rate was 84.4% and 92.3%, respectively (P = 0.327) and the 5-year overall survival rate was 88.9% and 92.3%, respectively, for the two groups (P = 0.692). The disease progression was not significantly associated with the pretreatment clinical stage in ypstage I group. The 5-year disease progression rate was 10.5% and 19.2%, respectively, for the patients who received adjuvant chemotherapy and for those who rejected chemotherapy in the ypstage I group (P = 0.681). CONCLUSION: The oncologic outcomes of primary and post-irradiated early stage rectal cancer are similar. Patients with ypstage I rectal cancer may slightly benefit from adjuvant chemotherapy.
Entities:
Keywords:
Neoadjuvant radiotherapy; Rectal cancer; Total mesorectal excision
Authors: C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: C A Marijnen; I D Nagtegaal; E Klein Kranenbarg; J Hermans; C J van de Velde; J W Leer; J H van Krieken Journal: J Clin Oncol Date: 2001-04-01 Impact factor: 44.544
Authors: Vincenzo Valentini; Cynthia Aristei; Bengt Glimelius; Bruce D Minsky; Regina Beets-Tan; Jose M Borras; Karin Haustermans; Philippe Maingon; Jens Overgaard; Lars Pahlman; Phil Quirke; Hans-Joachim Schmoll; David Sebag-Montefiore; Irving Taylor; Eric Van Cutsem; Cornelius Van de Velde; Numa Cellini; Paolo Latini Journal: Radiother Oncol Date: 2009-08 Impact factor: 6.280
Authors: George Theodoropoulos; W E Wise; A Padmanabhan; B A Kerner; C W Taylor; P S Aguilar; K S Khanduja Journal: Dis Colon Rectum Date: 2002-07 Impact factor: 4.585